scholarly journals Ovarian cancer with pleural and lung metastasis in Dr. Soetomo Hospital, Surabaya, Indonesia, in 2014-2015

2018 ◽  
Vol 26 (1) ◽  
pp. 7
Author(s):  
Fitria Khusnul Khotimah ◽  
Anna Febriani ◽  
Pungky Mulawardhana
Keyword(s):  
Ovarian Cancer ◽  
Survival Rate ◽  
Cancer Patients ◽  
Median Survival ◽  
Lung Metastasis ◽  
Survival Rates ◽  
Secondary Data ◽  
Pleural Metastasis ◽  
Histopathological Type ◽  
Median Survival Rate

Objectives: To know the characteristics of ovarian cancer patients with pleural and lung metastasis, and survival rates of ovarian cancer patients with pleural and lung metastasis in Dr. Soetomo Hospital Surabaya in 2014-2015.Materials & Methods: This was a descriptive observational study using secondary data from medical records in dr. Soetomo Hospital, Surabaya, Indonesia, in 2014 and 2015Results: Number of new patients of ovarian cancer in dr. Soe-tomo, Hospital, Surabaya in 2014 was 170 patients (14%) and 122 patients (12%) in 2015. Ovarian cancer patients most often came at the stage IIIC (33.38%) with the most histopathological type was epithelial ovarian cancer. There were 5 patients with ovarian cancer with pleural metastasis and 7 patients with lung metastasis. Pleural metastasis was 80% diagnosed at the time of ovarian cancer’s diagnosis, whereas 57.15% of lung metastasis were diag-nosed >12 months after the ovarian cancer’s diagnosis. Pleural metastasis was established by pleural fluid cytology, while lung metastasis with radiological features and/or biopsies. The most common feature of lung metastasis was nodal (71.42%). Ascites was found in 80% of ovarian cancer with pleural metastasis, but only 42.86% in lung metastasis. In 2 patients receiving NAC chemotherapy and continued by interval debulking, both had negative residues. Median survival rate in ovarian cancer with pleural metastasis was 7 months, whereas in lung metastasis was 12 months.Conclusions: Number of new patients of ovarian cancer in 2014-2015 in dr. Soetomo Hospital was on rising and was the second largest number of visits after cervical cancer. In 2014-2015, there were 5 patients with ovarian cancer and pleural metastasis and 7 patients with ovarian cancer patients and lung metastasis. Median survival rate in ovarian cancer with pleural metastasis was 7 months, whereas in lung metastasis it was 12 months.

scholarly journals Ovarian cancer with pleural and lung metastasis in Dr. Soetomo Hospital, Surabaya, Indonesia, in 2014-2015

2018 ◽  
Vol 26 (1) ◽  
pp. 7
Author(s):  
Fitria Khusnul Khotimah ◽  
Anna Febriani ◽  
Pungky Mulawardhana
Keyword(s):  
Ovarian Cancer ◽  
Survival Rate ◽  
Cancer Patients ◽  
Median Survival ◽  
Lung Metastasis ◽  
Survival Rates ◽  
Secondary Data ◽  
Pleural Metastasis ◽  
Histopathological Type ◽  
Median Survival Rate

Objectives: To know the characteristics of ovarian cancer patients with pleural and lung metastasis, and survival rates of ovarian cancer patients with pleural and lung metastasis in Dr. Soetomo Hospital Surabaya in 2014-2015.Materials & Methods: This was a descriptive observational study using secondary data from medical records in dr. Soetomo Hospital, Surabaya, Indonesia, in 2014 and 2015Results: Number of new patients of ovarian cancer in dr. Soe-tomo, Hospital, Surabaya in 2014 was 170 patients (14%) and 122 patients (12%) in 2015. Ovarian cancer patients most often came at the stage IIIC (33.38%) with the most histopathological type was epithelial ovarian cancer. There were 5 patients with ovarian cancer with pleural metastasis and 7 patients with lung metastasis. Pleural metastasis was 80% diagnosed at the time of ovarian cancer’s diagnosis, whereas 57.15% of lung metastasis were diag-nosed >12 months after the ovarian cancer’s diagnosis. Pleural metastasis was established by pleural fluid cytology, while lung metastasis with radiological features and/or biopsies. The most common feature of lung metastasis was nodal (71.42%). Ascites was found in 80% of ovarian cancer with pleural metastasis, but only 42.86% in lung metastasis. In 2 patients receiving NAC chemotherapy and continued by interval debulking, both had negative residues. Median survival rate in ovarian cancer with pleural metastasis was 7 months, whereas in lung metastasis was 12 months.Conclusions: Number of new patients of ovarian cancer in 2014-2015 in dr. Soetomo Hospital was on rising and was the second largest number of visits after cervical cancer. In 2014-2015, there were 5 patients with ovarian cancer and pleural metastasis and 7 patients with ovarian cancer patients and lung metastasis. Median survival rate in ovarian cancer with pleural metastasis was 7 months, whereas in lung metastasis it was 12 months. 

State of the Russian Oncology Service: malignant neoplasms of the tongue C01, 02 (mortality rate in patients, median survival of patients, taking into account the stage of the disease and the histological structure of the tumor). Part II

2021 ◽  
Author(s):  
Vakhtang M. Merabishvili ◽  
Elvira N. Merabishvili ◽  
Alexander M. Shcherbakov ◽  
Alexander B. Vasiliev ◽  
Alexey F. Barsukov ◽  
...  
Keyword(s):  
Survival Rate ◽  
Mortality Rate ◽  
Cancer Patients ◽  
Median Survival ◽  
Tongue Cancer ◽  
Survival Rates ◽  
Relative Survival ◽  
Population Based ◽  
Malignant Neoplasms ◽  
Oncology Service

Malignant neoplasms of the tongue occupy 0.55% in the general structure of the cancer incidence in Russian population. No information on other parameters (the number of deaths, mortality of patients, their distribution by stages of the disease and other analytical indicators) is provided in the official reporting. The opportunity appeared only with the development of Population-based Cancer Registries (PCR) system, but this wealth of material is not used for the official reporting. Tongue cancer is a visual localization with a high mortality rate, which requires special attention. The study was conducted to investigate the state of Russian Oncology Service for tongue cancer patients with the calculations of one-year mortality rate, annual mortality rate, median survival, 1,3,5-year observed and relative survival rates, first time in Russia, at the level of the newly created Population-based Cancer Registry of the Federal District. In Russia, there has been little research on the analysis of the cancer survival rate at the population level. We have been conducting developments for all malignant tumors localizations since 2000 based on the St. Petersburg PCR database. The level of 5-year observed and relative survival rates for tongue cancer patients in Russia (St. Petersburg and the NWFD RF) has been found to be significantly lower than the EU average (Eurocare-4). To carry out this study, 5188 observations from the NWFD RF PCR database were selected. It has been established that during 4 periods of observation, the mortality rate for tongue cancer patients during the first year of observation in the NWFD RF has decreased under the C01 rubric (cancer of the base of the tongue) from 58.5 to 45.8%; and under the C02 rubric (malignant neoplasm of other and unspecified parts of tongue) from 54.5 to 42.7%. The five-year survival rate for tongue cancer patients has increased by 23.3%.

scholarly journals Period Analysis of Intraracial Differences in Incidence and Survival Rates in Epithelial Ovarian Cancer

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Lili Han ◽  
Sulaiya Husaiyin ◽  
Jing Liu ◽  
Miherinisha Maimaiti ◽  
Mayinuer Niyazi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Survival Rate ◽  
Epithelial Ovarian Cancer ◽  
Median Survival ◽  
Survival Rates ◽  
Relative Survival ◽  
Population Based ◽  
Relative Survival Rate ◽  
Kaplan Meier ◽  
The Difference

Background. To explain the difference in the incidence and relative survival in a population-based cohort of women with epithelial ovarian cancer (EOC) postdiagnosis in the last forty years. EOC is the most common type of all ovarian cancers, but there is inadequate information about the variations related to long-term EOC survival. Methods. We acquired the incidence and relative survival rate data from the Surveillance, Epidemiology, and End Results (SEER) registries to analyze the epidemiological variations from 1974 to 2013 in EOC-affected individuals. The survival disparities in EOC-specific individuals due to age, race, and socioeconomic status (SES) were performed by Kaplan-Meier analysis. The Results. The overall incidence of EOC progressively declined to 9.0 per 100,000 from 11.4 in the last forty years. The median survival rate improved to 48 months in the first decade from a previous of 27 months in the fourth decade. The 5-year relative survival rate (RSR) increased to 44.3% that was previously 32.3% at the same time. However, between whites and blacks, an increase from 11 to 18 months was observed in the median survival differences. Between the low and high poverty groups, it was increased from 7 months to 12 months, respectively. Conclusions. The incidence rate of RSR and EOC-specific individuals in the last forty years was improved. However, the survival rates among different races and SES differed over time.

scholarly journals Development and Validation of Nomograms to Predict Lung Metastases in Patients with Ovarian Cancer: A Large Cohort Study

2020 ◽  
Author(s):  
Yufei Yuan ◽  
Fanfan Guo ◽  
Ruoran Wang ◽  
Yidan Zhang ◽  
GuiQin Bai
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Survival Rate ◽  
Cancer Patients ◽  
Lung Metastasis ◽  
Cox Regression ◽  
Validation Cohort ◽  
Lung Metastases ◽  
Overall Survival Rate ◽  
Newly Diagnosed

Abstract Background Lung metastasis, an independent risk factor affecting the prognosis of patients with ovarian cancer, is associated with poor survival. We tried to develop and validate a nomogram to predict the risk of lung metastases in newly diagnosed patients with ovarian cancer.Methods Patients diagnosed with ovarian cancer from the surveillance, epidemiology and final results (SEER) database between 2010 and 2015 were retrospectively collected. The model nomogram was built based on logistic regression. The consistency index (C-index) was used to evaluate the discernment of the lung metastasis nomogram. Calibration plots was drawn to analyze the consistency between the observed probability and predicted probability of lung metastases in patients with ovarian cancer. The Kaplan-Meier method was used to estimate the overall survival rate, and the influencing factors were included in the multivariate Cox regression (P<0.05) to analyze the independent prognostic factors of lung metastases.Results A total of 16,059 eligible patients were randomly divided into training (n = 11242) and validation cohort (n = 4817). AJCC T, N stage, bone metastases, brain metastases and liver metastases were evaluated as predictors of lung metastases. Finally, a nomogram was constructed. The nomogram based on independent predictors was well calibrated and showed good discriminative ability. The C index is 0.761 (0.736-0.787) for the training cohort and 0.757（0.718-0.795）for the validation cohort. The overall survival rate of ovarian cancer patients with lung metastases was reduced. Mixed histological types, chemotherapy and primary site surgery were factors that affect the overall survival of ovarian cancer patients with lung metastases.Conclusion: The clinical prediction model had high accuracy and can be used to predict the lung metastasis risk of newly diagnosed patients with ovarian cancer, which can guide the treatment of patients with lung metastases.

scholarly journals Survival after surgery among patients with cholangiocarcinoma in Northeast Thailand according to anatomical and morphological classification

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Chaiwat Tawarungruang ◽  
Narong Khuntikeo ◽  
Nittaya Chamadol ◽  
Vallop Laopaiboon ◽  
Jaruwan Thuanman ◽  
...  
Keyword(s):  
Survival Rate ◽  
Survival Time ◽  
Median Survival ◽  
Median Survival Time ◽  
Cox Regression ◽  
Survival Rates ◽  
Care Program ◽  
Tumor Location ◽  
Northeast Thailand ◽  
Curative Surgery

Abstract Background Cholangiocarcinoma (CCA) has been categorized based on tumor location as intrahepatic (ICCA), perihilar (PCCA) or distal (DCCA), and based on the morphology of the tumor of the bile duct as mass forming (MF), periductal infiltrating (PI) or intraductal (ID). To date, there is limited evidence available regarding the survival of CCA among these different anatomical and morphological classifications. This study aimed to evaluate the survival rate and median survival time after curative surgery among CCA patients according to their anatomical and morphological classifications, and to determine the association between these classifications and survival. Methods This study included CCA patients who underwent curative surgery from the Cholangiocarcinoma Screening and Care Program (CASCAP), Northeast Thailand. The anatomical and morphological classifications were based on pathological findings after surgery. Survival rates of CCA and median survival time since the date of CCA surgery and 95% confidence intervals (CI) were calculated. Multiple cox regression was performed to evaluate factors associated with survival which were quantified by hazard ratios (HR) and their 95% CIs. Results Of the 746 CCA patients, 514 had died at the completion of the study which constituted 15,643.6 person-months of data recordings. The incidence rate was 3.3 per 100 patients per month (95% CI: 3.0–3.6), with median survival time of 17.8 months (95% CI: 15.4–20.2), and 5-year survival rate of 24.6% (95% CI: 20.7–28.6). The longest median survival time was 21.8 months (95% CI: 16.3–27.3) while the highest 5-year survival rate of 34.8% (95% CI: 23.8–46.0) occurred in the DCCA group. A combination of anatomical and morphological classifications, PCCA+ID, was associated with the longest median survival time of 40.5 months (95% CI: 17.9–63.0) and the highest 5-year survival rate of 42.6% (95% CI: 25.4–58.9). The ICCA+MF combination was associated with survival (adjusted HR: 1.45; 95% CI: 1.01–2.09; P = 0.013) compared to ICCA+ID patients. Conclusions Among patients receiving surgical treatment, those with PCCA+ID had the highest 5-year survival rate, which was higher than in groups classified by only anatomical characteristics. Additionally, the patients with ICCA+MF tended to have unfavorable surgical outcomes. Showed the highest survival association. Therefore, further investigations into CCA imaging should focus on patients with a combination of anatomical and morphological classifications.

scholarly journals The Clinicopathologic Characteristics and 3-Year Survival Rates of Epithelial Ovarian Cancer in Iran During 2011-2017

2018 ◽  
Vol 7 (4) ◽  
pp. 496-500
Author(s):  
Shahrzad Sheikh Hasani ◽  
Mitra Modares Gilani ◽  
Setareh Akhavan ◽  
Azam-Sadat Mousavi ◽  
Elham Saffarieh ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Survival Rate ◽  
Epithelial Ovarian Cancer ◽  
Mucinous Adenocarcinoma ◽  
Survival Rates ◽  
Newly Diagnosed ◽  
Clinicopathologic Characteristics ◽  
Cross Sectional ◽  
Treatment Type

Objectives: The aim of this study was to determine the 3-year overall survival among the epithelial ovarian cancer patients based on the histology, age, and the stage of the disease in Iran during 2011-2017. Materials and Methods: This study was a cross-sectional retrospective study that was conducted on 179 newly diagnosed patients with epithelial ovarian cancer, who had referred to the gynecologic cancers clinic in a referral training hospital in Tehran during 2011-2017. The patients’ data including the demographic characteristics of the patients, the stage of the disease, and the treatment type were analyzed based on the pathologic responses. Results: Among 220 newly diagnosed patients with epithelial ovarian cancer, 179 of them were suitable for the follow-up. There were 93 death and 85 living cases among these patients and the mean age of the patients was 50.5 ± 11.3. In addition, most of the patients were in stage 3 (60.9%) and 6.7% of them were in stage 4. The most common pathology was serous adenocarcinoma (70.9%). In this study, the overall survival rate had no connection with the type of tumor histology but it was related to the stage of the disease (P=0.05). Finally, there was no mortality in stage one and among the mucinous adenocarcinoma cases. Conclusions: The survival in the epithelial ovarian cancer was related to the stage of the disease and among all the pathologies, mucinous adenocarcinoma and clear cell carcinoma had the best survival rate.

scholarly journals Evaluation of chemotherapy response between Paclitaxel-Cisplatin, Paclitaxel -Gemcitabine and Gemcitabine - Cisplatin among non - resectable lung cancer patients, A retrospective study in tertiary care hospital.

2020 ◽  
Vol 38 (4) ◽  
pp. 172-175
Author(s):  
Md Harun Or Rashid ◽  
Quadrat E Elahi ◽  
Md Ashraful Alam ◽  
Fatima Sarker
Keyword(s):  
Lung Cancer ◽  
Survival Rate ◽  
Survival Time ◽  
Cancer Patients ◽  
Median Survival ◽  
Median Survival Time ◽  
Chemotherapy Response ◽  
Care Hospital ◽  
Lung Cancer Patients ◽  
Significant Difference

Background: To compare the survival rate of paclitaxel plus cisplatin (PC arm), paclitaxel plus gemcitabine (PG arm) and gemcitabine plus cisplatin (GC arm) in chemotherapy patients with non resectable lung cancer. Methods: This was a retrospective observational study to evaluate chemotherapy response among non resectable lung cancer patients with their survival at cancer center CMH, Dhaka since 01 July 2013 to 31 March 2015. One hundred fifty-four (154) non resectable lung cancer patients were randomly divided into three groups, 50 patients in PC arm, 51 patients in PG arm and 53 patients in GC arm. In PC arm paclitaxel 175 mg/m2 (day 1) with cisplatin 75mg/m2 (day 1), in PG arm Paclitaxel 175 mg/m2 (day 1) with gemcitabine 1000 mg/m2 (days 1 and 8) and in GC arm gemcitabine 1000 mg/m2 (days 1 and 8) with cisplatin 100mg/m2 (day 1). Results: Patients characteristics were similar between the three groups. The overall response rate was 40% in the PC arm,43.1% in the PG arm, 43.4% in the GC arm. The median survival time in PC arm was 8.5 months, in PG arm was 8.8 months, in GC arm was 9.2 months. The major side effect was myelosuppression which accounts 71% patients. The average treatment costs were 57% and 30% lower in PC arm as compared with GC and PG arm respectively. Conclusion: The median survival time, disease free survival time and 1-year survival rate in PC, PG, GC arms without significant difference. Treatment were well tolerable; quality of life parameter was mostly similar but paclitaxel with cisplatin was most cost effective than others chemotherapy regimen. J Bangladesh Coll Phys Surg 2020; 38(4): 172-175

scholarly journals Survival of cervical cancer patients and its prognostic factors at Cipto Mangunkusumo Hospital, Jakarta

2014 ◽  
Vol 23 (3) ◽  
pp. 163-8 ◽  
Author(s):  
Laila Nuranna ◽  
Rahma Prastasari ◽  
Bambang Sutrisna
Keyword(s):  
Cervical Cancer ◽  
Prognostic Factors ◽  
Survival Rate ◽  
Cancer Patients ◽  
Median Survival ◽  
Survival Probability ◽  
Cancer Survival ◽  
Stage Iii ◽  
Cox Regression Analysis ◽  
Lower Survival

Background: Cervical cancer is the second most common cancer among Indonesian women. Information concerning survival probability is very important for the patient and institution. Our last data about cervical cancer survival was studied for more than 10 years ago. This study aimed to know the latest cervical cancer survival and its prognostic factors.Methods: This is a retrospective cohort study which enrolled cervical cancer patients treated at Cipto Mangunkusumo Hospital in 2005-2006. Subjects were followed-up for minimum of 5 years. Kaplan-Meier and Cox regression analysis was used to determine the survival probability and to assess prognostic factors.Results: A total of 447 patients who met the study criteria were selected. Stage III was the largest proportion on the study (41.6%). Most of the histopathology type was squamous cell carcinoma (71.6%). This study revealed that median survival was 63 months with the overall 5-years survival probability to be 52%. Tumor size did not influence overall survival rate. Stage III and IV had lower survival probability (HR 3.27 and 6.44). Poor differentiation and uncompleted therapy also had lower survival probability (HR 2.26 and 2.22). Histopathology of others (neuroendocrine) had lower survival probability (HR 2.85). However, it was not statistically significant on multivariate analysis.Conclusion: Median survival time for cervical cancer patients at Cipto Mangunkusumo Hospital was 63 months. There were improvement in the survival rate comparing from the study in 1997. In this study, the independent prognostic factors for survival were tumor staging, tumor differentiation, and completion of therapy.

Prostate cancer patient’s survival in Lithuania

2013 ◽  
Vol 19 (4) ◽  
pp. 439-444
Author(s):  
Giedrė Smailytė ◽  
Robertas Adomaitis ◽  
Karolis Ulinskas ◽  
Birutė Aleknavičienė
Keyword(s):  
Prostate Cancer ◽  
Survival Rate ◽  
Cancer Patients ◽  
Rural Areas ◽  
Survival Rates ◽  
Relative Survival ◽  
Care Quality ◽  
Place Of Residence ◽  
Icd 10 ◽  
Survival Differences

Background. The aim of this study was to evaluate changes in the survival of prostate cancer patients during the 12-year period and to analyze differences in survival by period of diagnosis, stage of disease, age and place of residence. Materials and methods. All newly diagnosed cases of prostate cancer (ICD-10, C61) in men were identified in the Lithuanian Cancer Registry for the period 1994–2005. Five-year relative survival estimates were computed with the Hakulinen method using the STATA software. Five-year relative survival estimates were calculated for three different periods of time when prostate cancer was diagnosed (1994–1997, 1998–2001 and 2002–2005), by age (15–59, 60–74, and 75–99), stage at diagnosis (I, II, III, IV, unknown) and place of residence (cities and towns or rural areas). Results. The survival of prostate cancer patients in Lithuania has dramatically increased. Five-year relative survival in the period 1994–1997 was 46.92% and in the period 2002–2005 it reached 86.49%. Medium age prostate cancer patients (60–74 years) compared to younger and older patients had better survival rates. Increasing survival was observed for all stages of disease. Lower five-year relative survival rate of prostate cancer patients was reported for men from villages or other rural areas compared to patients from cities and towns in all periods under study. Conclusions. The five-year survival rate of patients with prostate cancer has increased from 46.92% (95% CI 44.12–49.74) in 1994–1997 to 86.49% (95% CI 84.73–88.22) in 2002–2005 in Lithuania. The study identified survival differences by age and place of residence. Issues, such as access to care, quality of medical care, must be made equally available and accessible for the whole population with special attention to older men and men living in rural areas.

Final results of After-6 protocol 1: A phase III trial of observation versus 6 courses of paclitaxel (Pac) in advanced ovarian cancer patients in complete response (CR) after platinum-paclitaxel chemotherapy (CT)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 5505-5505 ◽  
Author(s):  
P. F. Conte ◽  
G. Favalli ◽  
A. Gadducci ◽  
D. Katsaros ◽  
P. L. Benedetti Panici ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Survival Rates ◽  
Advanced Ovarian Cancer ◽  
Stage Iv ◽  
Experimental Treatment ◽  
Progression Free Survival ◽  
Phase Iii ◽  
First Line ◽  
Absolute Increase

5505 Background: The majority of advanced ovarian cancer patients (pts) in CR after debulking surgery and Platinum/Paclitaxel will eventually relapse. Role of maintenance CT is still questionable even if a SWOG/GOG trial has shown an improved progression free survival (PFS) with 12 vs 3 cycles of maintenance Pac. In March 1999, the After 6 Italian Cooperative Group initiated a phase III study to determine if maintenance Pac could prolong PFS in pts with a clinical (cCR) or pathological CR (pCR) after first line CT Methods: Pts with advanced ovarian cancer in cCR or pCR after 6 cycles of Platinum/Paclitaxel, were randomised to observation or 6 cycles of Pac 175 mg/sqm iv q 3 wks. Primary end point: PFS; secondary end points: overall survival (OS) and toxicities. Planned sample size: 250 pts to detect a 15% absolute increase in 2-yr PFS. Results: From 03/99 to 07/06, 200 pts were randomised. Due to the low accrual rate, an unplanned interim analysis of futility according to the Bayesian approach was performed. Main patient characteristics: median age 58 yrs, median PS 0 (neurotoxicity ≥ G 2 was an exclusion criteria), stage IIb/IIc 15%, stage III 79%, stage IV 6%; 105 pts (52.5%) were in pCR. 14% of pts randomised to observation received Pac; 22% of pts randomised to Pac stopped treatment after 2–5 cycles (progression or death: 3 pts; toxicity: 9 pts; refusal: 7 pts; others: 3 pts). A G ≥ 2 neurotoxicity was reported in 25% of pts treated with Pac; other toxicities were mild. After a median follow up of 44 months, 94 pts (47%) have relapsed and 42 pts (21%) died. Median PFS were 34 and 34.5 months in observation and Pac arm respectively; 3-yr OS was 88% in observation and 78% in Pac arm. Irrespectively of treatment arm, median PFS was 34.4 months for pts with pCR and 24.5 months for those with cCR; 3-yr survival rates were 87% and 79% respectively (p=0.04). Conclusions: Six courses of maintenance Pac do not prolong PFS or OS in pts in CR after first line platinum/paclitaxel. Irrespectively of assigned treatment, the outcome of these pts is more favourable than previously reported and significantly better in the pCRs. Maintenance CT remains an experimental treatment that should be tested in pts at high risk of relapse. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document